Beiersdorf


No clear growth in sight

03/03/26 -"Beiersdorf closed FY25 with a top line broadly in line with consensus and slightly better margin expansion, supported by continued double-digit Derma growth and sequential improvement at La Prairie ..."

Pages
54
Language
English
Published on
03/03/26
You may also be interested by these reports :
03/03/26
Beiersdorf closed FY25 with a top line broadly in line with consensus and slightly better margin expansion, supported by continued double-digit Derma ...

25/02/26
Haleon reported full-year results with sales slightly below consensus, though profitability exceeded expectations. Top-line growth was driven by ...

25/02/26
Q4 showed early signs of stabilisation, driven by a rebound in Blade Excellence, but core stationery and lighters remain under pressure. FY25 ...

18/02/26
Puig delivered a stronger-than-expected Q4 25, lifting FY25 results above expectations on the back of exceptional makeup growth and better resilience ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO